FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
